Panobinostat - Novartis

Drug Profile

Panobinostat - Novartis

Alternative Names: Faridak; Farydak; LBH-589; LBH-589A

Latest Information Update: 23 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Georgia Regents University; H. Lee Moffitt Cancer Center and Research Institute; HOVON Foundation; Icahn School of Medicine at Mount Sinai; Mayo Clinic; National Cancer Institute (USA); New York University School of Medicine; Novartis; Peter MacCallum Cancer Centre; St. Jude Childrens Research Hospital; Therapeutic Advances in Childhood Leukemia & Lymphoma; Thomas Jefferson University; University of Aarhus; University of Texas M. D. Anderson Cancer Center; University of Wisconsin-Madison
  • Class Antineoplastics; Hydroxamic acids; Indoles; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase II/III Chronic myeloid leukaemia
  • Phase II Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myelomonocytic leukaemia; Colorectal cancer; Graft-versus-host disease; Lymphoma; Myelodysplastic syndromes; Myelofibrosis; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Renal cell carcinoma; Thyroid cancer; Waldenstrom's macroglobulinaemia
  • Phase I/II Breast cancer; HIV-1 infections; Hodgkin's disease; Malignant melanoma
  • Phase I Brain metastases; CNS cancer; Gastrointestinal stromal tumours; Head and neck cancer; Mantle-cell lymphoma; Non-small cell lung cancer; Solid tumours
  • Preclinical Small cell lung cancer
  • No development reported Glioma; Pancreatic cancer
  • Discontinued Cutaneous T cell lymphoma; Prostate cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 14 May 2018 Novartis initiates the phase I/II HOVON 148 AML trial for Acute myeloid leukaemia (Combination therapy) in Netherlands (PO) (NTR6511) (EudraCT2017-002335-42)
  • 11 Mar 2018 Novartis Pharmaceuticals terminates a phase II trial in Lymphoma (Combination therapy, In adolescents, In adults, In children, In infants, Salvage therapy, Second-line therapy or greater) in USA (PO) (NCT02518750)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top